EXO-NET is initially being commercialised as an exosome isolation tool for use in the rapidly growing exosome research market with the goal of embedding the technology into research applications that may underpin future licensing of EXO-NET for use in the development and commercialisation of exosome-based diagnostic and therapeutic applications. EXO-NET pan-exosome capture tool was initially test marketed to exosome researchers inMay 2021. During FY22, INOVIQ completed multiple positive evaluations of its EXO-NET product with leading Australian and international research groups with the goal of gaining product endorsement, generating future sales or securing future collaborations for development of exosome-based diagnostics for cancer, neurodegenerative disease and other indications. Researchers compared EXO-NET to existing exosome isolation technologies with positive results for their biomarkers of interest. On 10 November 2021, INOVIQ sponsored and attended the virtual Australia & New Zealand Society of Extracellular Vesicles (ANZSEV) Symposium to promote and educate researchers about the benefits of EXO-NET. A copy of the conference presentation is available via INOVIQ’s investor centre at www.inoviq.com/site/investors/presentations. On 1 April 2022, INOVIQ announced its first EXO-NET collaboration with the University of Queensland (UQ) to develop a world-first exosome-based ovarian cancer screening test using INOVIQ’s EXO-NET technology and UQ’s biomarkers. This blood test could fill an important unmet need for an accurate and reliable screening test for ovarian cancer to improve women’s health outcomes and save lives. On 26 April 2022, a Scientific Statement, co-authored by INOVIQ’s Chief Scientific Officer Professor Greg Rice, entitled “Extracellular vesicles and their emerging roles as cellular messengers in endocrinology: An Endocrine Society Scientific Statement” was published in the Endocrine Society’s high impact scientific journal Endocrine Reviews. The paper is available at https://doi. org/10.1210/endrev/bnac009. EXO-NET® pan-exosome capture 11 Annual Report 2022
RkJQdWJsaXNoZXIy MjE2NDg3